Figure 2: PASI score reduction in each group and by treatment. In cases classified as IFX-appropriate, a significant difference in score reduction was noted between patients treated with infliximab and those treated with adalimumab, and between patients treated with ustekinumab and those treated with adalimumab. In cases classified as ADA-appropriate, no significant differences were noted between any treatment groups. In cases classified as UST-appropriate, a significant difference in score reduction was noted between those treated with adalimumab and those treated with ustekinumab.